A second global pivotal trial will test iza-bren in the same NSCLC setting where patri-dxd failed.
ApexOnco Front Page
Recent articles
If Pfizer hands back the estrogen receptor degrader, Arvinas will seek a new partner.
Fuelled with a $500m Summit windfall Akeso advances its lead bispecific.
When autogene cevumeran works it seems to keep working, but bigger tests for the project have been pushed back.
The group was a first mover in stage III NSCLC, and now it hopes to repeat the trick in SCLC.
The company looks rash for promising Tamarack data at the conference, although at least vobra duo’s safety has improved.
The company is setting up another battle with Bristol Myers Squibb, while Amgen has different plans.
April will see the first big scientific meeting of the year, and could herald important data from Immutep and GSK.